A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...
BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...
The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...
Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a ...
The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...
Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...
Investing.com -- Adagene Inc (NASDAQ:ADAG) stock surged 16.3% in premarket trading Tuesday after the company announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation ...
Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback